| Autor: |
Ruiz-Arenas R; Alianza Mexicana para Prevenir las Enfermedades Crónicas, A.C. (AMPEC)., Sierra-Amor R; Alianza Mexicana para Prevenir las Enfermedades Crónicas, A.C. (AMPEC)., Seccombe D; CEQAL Inc., Vancouver, British Columbia, Canada., Raymondo S; Asociación Bioquímica Uruguaya (ABU)., Graziani MS; Italian Society of Clinical Chemistry and Clinical Molecular Biology (SIBioC)., Panteghini M; Italian Society of Clinical Chemistry and Clinical Molecular Biology (SIBioC)., Adedeji TA; Association of Clinical Chemists of Nigeria (ACCN)., Kamatham SN; Association of Medical Biochemists of India (AMBI)., Biljak VR; Croatian Society of Medical Biochemistry and Laboratory Medicine (CSMBLM). |
| Jazyk: |
angličtina |
| Zdroj: |
EJIFCC [EJIFCC] 2017 Dec 19; Vol. 28 (4), pp. 302-314. Date of Electronic Publication: 2017 Dec 19 (Print Publication: 2017). |
| Abstrakt: |
Chronic kidney disease (CKD) is a major public health issue worldwide and is associated with adverse health outcomes, especially in low- and middle-income countries. In a cash limited healthcare system, guidelines that improve the efficiency of health care free up resources needed for other healthcare services. This short review presents some examples from national acitivities in CKD testing, including countries throughout the globe: Mexico in North America, Uruguay in South America, Italy in Europe, Nigeria in Africa and India in Asia. Considering the fact that treatment of CKD is cost-effective and improves outcomes, this observation argue in favor of including CKD in national guidelines and noncommunicable chronic disease (NCD) programs. This diverse example of national activities fullfil the very first step in achieving this goal. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
